|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Serum Alpha-1 Antitrypsin Levels and the Clinical Course of Chronic Obstructive Pulmonary Disease
This item is licensed under:Creative Commons Attribution-NonCommercial 3.0 Unported
| Title: | Serum Alpha-1 Antitrypsin Levels and the Clinical Course of Chronic Obstructive Pulmonary Disease |
| Authors: | Takei, Nozomu Browse this author | | Suzuki, Masaru Browse this author →KAKEN DB | | Makita, Hironi Browse this author →KAKEN DB | | Konno, Satoshi Browse this author →KAKEN DB | | Shimizu, Kaoruko Browse this author →KAKEN DB | | Kimura, Hiroki Browse this author →KAKEN DB | | Kimura, Hirokazu Browse this author | | Nishimura, Masaharu Browse this author →KAKEN DB |
| Keywords: | chronic obstructive pulmonary disease | | alpha-1 antitrypsin | | inflammation | | lung function decline | | mortality |
| Issue Date: | 10-Dec-2019 |
| Publisher: | Dove Medical Press |
| Journal Title: | International journal of chronic obstructive pulmonary disease |
| Volume: | 14 |
| Start Page: | 2885 |
| End Page: | 2893 |
| Publisher DOI: | 10.2147/COPD.S225365 |
| Abstract: | Purpose: Alpha-1 antitrypsin deficiency is associated with the development of chronic obstructive pulmonary disease (COPD), whereas increased levels of serum alpha-1antitrypsin occur in response to inflammation. The effects of alpha-1 antitrypsin levels on the clinical course of COPD had been unclear. We investigated the association of serum alpha-1 antitrypsin levels with the clinical course of COPD patients based on data from a 10-year prospective cohort study. Patients and methods: We analyzed 278 COPD patients who participated in the Hokkaido COPD cohort study and who did not meet the criteria for alpha-1 antitrypsin deficiency. We divided the subjects into 3 groups according to quartiles of serum alpha-1 antitrypsin levels at baseline: lower group (<116 mg/dL, n = 66); middle group (116 to <= 141 mg/dL, n = 145); and higher group (>141 mg/dL, n = 67). The annual change in forced expiratory volume in 1 s (FEV1) and events of COPD exacerbation were monitored during the first 5 years, and mortality was followed-up during the entire 10 years. Results: At baseline, the higher group showed lower body mass index; higher computed tomography emphysema score; lower diffusing capacity; higher levels of acute-phase proteins; and higher blood neutrophil counts. Longitudinal analyses revealed that in the higher group, the annual decline in FEV1 was rapid and the 10-year mortality was higher, but there was no association between serum alpha-1 antitrypsin levels and time to first exacerbation. Conclusion: COPD subjects with higher serum alpha-1 antitrypsin levels were associated with a worse systemic inflammation status and higher 10-year mortality. |
| Rights: | https://creativecommons.org/licenses/by-nc/3.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/76623 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
